# Developmental Therapeutics Program

## One Dose Mean Graph

| | | |
|---|---|---|
| **NSC:** 767968 / 1 | **Conc:** 1.00E-5 Molar | **Test Date:** Oct 22, 2012 |
| **Experiment ID:** 1210OS70 | | **Report Date:** Nov 29, 2012 |

| Panel/Cell Line | Growth Percent |
|---|---|
| Leukemia | |
| CCRF-CEM | 97.40 |
| HL-60(TB) | 112.90 |
| K-562 | 86.67 |
| MOLT-4 | 95.50 |
| RPMI-8226 | 94.00 |
| SR | 86.20 |
| Non-Small Cell Lung Cancer | |
| A549/ATCC | 102.75 |
| HOP-62 | 104.17 |
| HOP-92 | 96.05 |
| NCI-H226 | 89.22 |
| NCI-H23 | 108.93 |
| NCI-H322M | 98.96 |
| NCI-H460 | 105.40 |
| NCI-H522 | 90.59 |
| Colon Cancer | |
| COLO 205 | 105.55 |
| HCC-2998 | 123.51 |
| HCT-116 | 104.35 |
| HCT-15 | 99.22 |
| HT29 | 103.25 |
| KM12 | 106.63 |
| SW-620 | 104.04 |
| CNS Cancer | |
| SF-268 | 102.45 |
| SF-539 | 98.72 |
| SNB-19 | 106.15 |
| SNB-75 | 83.67 |
| U251 | 100.28 |
| Melanoma | |
| LOX IMVI | 98.39 |
| MALME-3M | 103.48 |
| M14 | 106.55 |
| MDA-MB-435 | 99.52 |
| SK-MEL-2 | 104.88 |
| SK-MEL-28 | 105.02 |
| SK-MEL-5 | 98.68 |
| UACC-257 | 100.80 |
| UACC-62 | 102.36 |
| Ovarian Cancer | |
| IGROV1 | 102.41 |
| OVCAR-3 | 112.44 |
| OVCAR-4 | 101.91 |
| OVCAR-5 | 110.03 |
| OVCAR-8 | 97.09 |
| NCI/ADR-RES | 106.01 |
| SK-OV-3 | 107.97 |
| Renal Cancer | |
| 786-0 | 100.15 |
| A498 | 103.62 |
| ACHN | 98.68 |
| CAKI-1 | 93.45 |
| RXF 393 | 97.72 |
| SN12C | 101.70 |
| TK-10 | 112.26 |
| UO-31 | 100.26 |
| Prostate Cancer | |
| PC-3 | 94.59 |
| DU-145 | 109.51 |
| Breast Cancer | |
| MCF7 | 99.25 |
| MDA-MB-231/ATCC | 103.08 |
| HS 578T | 106.46 |
| BT-549 | 99.89 |
| T-47D | 93.98 |
| MDA-MB-468 | 100.07 |
| Mean | 101.36 |
| Delta | 17.69 |
| Range | 39.84 |

**Mean Growth Percent - Growth Percent**